RecruitingPhase 1NCT07276958

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

A Phase 1, Multicenter, Randomized, Placebo-Controlled, Participant-Blind, Single-Ascending Dose Study of LY4298445 in Healthy Participants and an Open-Label Single-Ascending Dose and Multiple-Ascending Dose Study of LY4298445 in Participants With Systemic Lupus Erythematosus or Rheumatoid Arthritis

Sponsor

Eli Lilly and Company

Enrollment

63 participants

Start Date

Feb 4, 2026

Study Type

INTERVENTIONAL

Conditions

Rheumatoid Arthritis Healthy Systemic Lupus Erythematosus

Summary

The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called LY4298445 and a drug called LY4298445 for people with healthy, rheumatoid arthritis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLY4298445

Administered SC

DRUGLY4298445

Administered IV

Locations(9)

Nucleus Network

Brisbane, Australia

Nucleus Network

Melbourne, Australia

Peking University First Hospital

Beijing, China

Peking University Third Hospital

Beijing, China

Xiangya Hospital of Central South University

Changsha, China

Anhui Provincial Hospital

Hefei, China

Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, China

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07276958

Related Trials

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325233 locations

Long-Term Effects of Walnut Consumption on Brain Function

NCT074222201 location

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight

NCT076932313 locations

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

NCT076203926 locations

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

NCT048334651 location